Lipitor Gains Prevention Indication For Patients With Normal Cholesterol
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer’s Lipitor approval for prevention of cardiovascular disease in patients with normal to mildly elevated cholesterol levels will give the firm a new indication to promote as the Merck/Schering joint venture rolls out its new combo cholesterol therapy Vytorin.